NCT01773148Unknown不适用
AXERA Access Safety and Efficacy Post Endovascular INtervention
适应症
干预措施
试验速览
- 阶段
- 不适用
- 入组人数
- 240
- 试验地点
- 17
- 主要终点
- Major Adverse Events
研究概览
简要总结
The goal of this study is to assess the safety and effectiveness of the AXERA Access System in subjects undergoing Common Femoral Artery (CFA) access for Percutaneous Coronary Intervention (PCI) and/or Peripheral Vascular Intervention (PVI) through a 5 French (F) or 6F introducer sheath.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is 18 years of age or older.
- •Subject is clinically indicated for a PCI or PVI involving access through a 5F or 6F introducer sheath in the femoral artery.
- •Subject is able to ambulate without assistance prior to the procedure and can be expected to ambulate (20 feet) within 2 hours post procedure.
- •Female subjects of child bearing potential must have a negative pregnancy test.
排除标准
- •Subjects who are pregnant or lactating.
- •Subject has a pre-existing severe non-cardiac systemic disease/illness or another reason that results in a projected life expectancy of less than 1 year.
- •Subject has an active systemic or cutaneous infection or inflammation (e.g., septicemia at the time of the procedure).
- •Subject has systemic hypertension unresponsive to treatment (>180mmHg systolic and >110mm diastolic).
- •Subject has significant bleeding coagulopathy or platelet disorder, (INR> 2.0), including known thrombocytopenia (platelet count <100,000/µL), thrombasthenia, Von Willebrand's disease, Factor V deficiency, or anemia (hemoglobin <10 g/dL, or hematocrit <30%).
- •Subject presents with chronic renal insufficiency (creatinine ≥3.0mg/dl).
- •Subject presents with hemodynamic instability or is in need of emergent surgery or emergent procedure.
- •Subject presents with ST elevation myocardial infarction.
- •Subject presents with unstable angina or non-ST elevation myocardial infarction and has troponin level > 3 X upper limit of normal. There must be at least one troponin level drawn > 6 hours after onset of chest pain.
- •Subject has received low molecular weight heparin < 8 hours before vascular access, glycoprotein IIb/IIIa inhibitor < 24 hours before vascular access, unfractionated heparin by infusion < 1 hour before vascular access, or parenteral heparin at anticoagulant dose (as opposed to DVT prophylaxis)< 6 hours before vascular access.
- •Subjects who are clinically obese, defined as BMI >
- •Subject has received femoral artery Vessel Closure Implant (VCI) (suture or staple) at the target access site.
- •Subject has received femoral artery VCI (collagen/PEG/PGA) at the target access site within 90 days of AXERA procedure.
- •Subject is unable to routinely walk at least 20 feet without assistance (e.g., requires a walker or wheelchair to mobilize, is leg amputee or has known paralysis) or unable to ambulate within 2 hours post procedure.
- •Subject has had prior vascular surgery or vascular grafts at the target femoral artery access site.
- •Subject has had a previous target femoral artery complication from angiography (such as pseudoaneurysm, Arteriovenous (AV) fistula, dissection), small CFA, abnormal, absent or weak distal ipsilateral pulse, or presenting with clinically significant peripheral vascular disease in the vicinity of the puncture.
- •Subject has a high puncture (i.e. above the inferior reflection of the inferior epigastric artery).
- •Subject has antegrade puncture.
- •Subject has a stent in the ipsilateral common femoral artery.
- •Subject is currently participating in an investigational drug or another device study that clinically interferes with the current study endpoints.
研究组 & 干预措施
Arstasis Access System (AXERA) placement
Experimental
Placement of AXERA device in subjects undergoing common femoral artery access for PCI and/or PVI through a 5F or 6F introducer sheath.
干预措施: Arstasis Access System (AXERA) (Device)
结局指标
主要结局
Major Adverse Events
时间窗: Procedure through 30 day follow-up.
Absence of major access site-related complications.
Device Success
时间窗: Day 1-Day of Procedure.
Defined as: * Successful placement of AXERA followed by procedural sheath * Achievement of hemostasis in conjunction with manual or mechanical compression
次要结局
- Time to Discharge, actual (TTD/a)(Evaluated following procedural sheath removal until actual discharge.)
- Minor Adverse Events(Procedure through 30 day follow-up.)
- Time to Hemostasis (TTH)(Immediately following procedural sheath removal.)
- Time to Ambulation (TTA)(Evaluated at any time after 2 hours post sheath removal, until the subject successfully ambulated.)
- Time to Discharge, eligibility (TTD/e)(Evaluated following sheath removal and ambulation and physical examination of the access site demonstrating stable access site.)
研究者
研究点 (17)
Loading locations...
相似试验
已完成
不适用
A Study to Evaluate the Safety and Performance of ArterX™ Vascular Sealant in Sealing Synthetic Arterial GraftsVascular DiseaseNCT02476318Tenaxis Medical, Inc.32
已完成
不适用
Novel Endovascular Access Trial (NEAT)Chronic Kidney DiseaseNCT02036671C. R. Bard80
已完成
不适用
HeRO Vascular Access Device Post Market Procedural Survey ProtocolEnd Stage Renal DiseaseNCT00889291Merit Medical Systems, Inc.77
已完成
不适用
A Patient Registry Evaluating Closure Following Access With the ArstasisOne Access SystemDiagnostic Catheterization Access Through a 5F or 6F Femoral Artery IntroducerNCT01271946Arstasis, Inc.351
进行中（未招募）
不适用
Ankura™ AAA, Cuff and AUI Stent Graft System Post-Market Clinical Follow-UpAbdominal Aortic AneurysmNCT05864560Lifetech Scientific (Shenzhen) Co., Ltd.164